176 related articles for article (PubMed ID: 20008773)
21. Virulence and antifungal therapy of murine disseminated infection by Rhodotorula mucilaginosa.
Thomson P; López-Fernández L; Guarro J; Capilla J
Diagn Microbiol Infect Dis; 2017 Sep; 89(1):47-51. PubMed ID: 28669678
[TBL] [Abstract][Full Text] [Related]
22. Experimental murine model of disseminated infection by Saksenaea vasiformis: successful treatment with posaconazole.
Salas V; Pastor FJ; Calvo E; Sutton D; García-Hermoso D; Mayayo E; Dromer F; Fothergill A; Alvarez E; Guarro J
Med Mycol; 2012 Oct; 50(7):710-5. PubMed ID: 22458251
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic/pharmacodynamic profile of posaconazole.
Li Y; Theuretzbacher U; Clancy CJ; Nguyen MH; Derendorf H
Clin Pharmacokinet; 2010 Jun; 49(6):379-96. PubMed ID: 20481649
[TBL] [Abstract][Full Text] [Related]
24. Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.
Simitsopoulou M; Gil-Lamaignere C; Avramidis N; Maloukou A; Lekkas S; Havlova E; Kourounaki L; Loebenberg D; Roilides E
Antimicrob Agents Chemother; 2004 Oct; 48(10):3801-5. PubMed ID: 15388437
[TBL] [Abstract][Full Text] [Related]
25. Experimental disseminated trichosporonosis in mice: tissue distribution and therapy with antifungal agents.
Yamamoto K; Makimura K; Sudo T; Shibuya K; Uchida K; Yamaguchi H
J Med Vet Mycol; 1997; 35(6):411-8. PubMed ID: 9467108
[TBL] [Abstract][Full Text] [Related]
26. Posaconazole.
Keating GM
Drugs; 2005; 65(11):1553-67; discussion 1568-9. PubMed ID: 16033292
[TBL] [Abstract][Full Text] [Related]
27. Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.
Calvo E; Pastor FJ; Mayayo E; Hernández P; Guarro J
Antimicrob Agents Chemother; 2011 Aug; 55(8):3709-13. PubMed ID: 21576429
[TBL] [Abstract][Full Text] [Related]
28. Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.
Zoller E; Valente C; Baker K; Klepser ME
Drug Des Devel Ther; 2010 Nov; 4():299-311. PubMed ID: 21116336
[TBL] [Abstract][Full Text] [Related]
29. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
Dolton MJ; Ray JE; Chen SC; Ng K; Pont L; McLachlan AJ
Antimicrob Agents Chemother; 2012 Nov; 56(11):5503-10. PubMed ID: 22890761
[TBL] [Abstract][Full Text] [Related]
30. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of triazoles in a murine disseminated infection by Candida krusei.
Mariné M; Pastor FJ; Serena C; Guarro J
Antimicrob Agents Chemother; 2009 Aug; 53(8):3585-8. PubMed ID: 19470509
[TBL] [Abstract][Full Text] [Related]
32. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
Krishna G; Sansone-Parsons A; Martinho M; Kantesaria B; Pedicone L
Antimicrob Agents Chemother; 2007 Mar; 51(3):812-8. PubMed ID: 17210771
[TBL] [Abstract][Full Text] [Related]
33. Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis.
Alkhazraji S; Gebremariam T; Alqarihi A; Gu Y; Mamouei Z; Singh S; Wiederhold NP; Shaw KJ; Ibrahim AS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818813
[TBL] [Abstract][Full Text] [Related]
34. Antifungal therapies in murine disseminated phaeohyphomycoses caused by Exophiala species.
Calvo E; Pastor FJ; Guarro J
J Antimicrob Chemother; 2010 Jul; 65(7):1455-9. PubMed ID: 20488983
[TBL] [Abstract][Full Text] [Related]
35. Posaconazole concentrations in human tissues after allogeneic stem cell transplantation.
Blennow O; Eliasson E; Pettersson T; Pohanka A; Szakos A; El-Serafi I; Hassan M; Ringdén O; Mattsson J
Antimicrob Agents Chemother; 2014 Aug; 58(8):4941-3. PubMed ID: 24890587
[TBL] [Abstract][Full Text] [Related]
36. Posaconazole: clinical pharmacology and potential for management of fungal infections.
Groll AH; Walsh TJ
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
[TBL] [Abstract][Full Text] [Related]
37. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.
Herbrecht R
Int J Clin Pract; 2004 Jun; 58(6):612-24. PubMed ID: 15311563
[TBL] [Abstract][Full Text] [Related]
38. Posaconazole: a next-generation triazole antifungal.
Farowski F; Vehreschild JJ; Cornely OA
Future Microbiol; 2007 Jun; 2(3):231-43. PubMed ID: 17661696
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic drug monitoring for triazoles.
Hope WW; Billaud EM; Lestner J; Denning DW
Curr Opin Infect Dis; 2008 Dec; 21(6):580-6. PubMed ID: 18978525
[TBL] [Abstract][Full Text] [Related]
40. Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.
Prattes J; Duettmann W; Hoenigl M
Antimicrob Agents Chemother; 2016 Sep; 60(9):5595-9. PubMed ID: 27324763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
